Capecitabine Monotherapy Does Not Improve Early-Stage Breast Cancer Survival in Elderly Patients
Capecitabine monotherapy does not improve outcomes in elderly patients with moderate- or high-risk early breast cancer.
San Antonio Breast Cancer Symposium (SABCS)
FEC-100 Not Superior to Adriamycin + Cyclophosphamide in Node-Negative Breast Cancer
FEC-100 does not yield improved outcomes over standard doxorubicin (adriamycin) with cyclophosphamide (AC) therapy in breast cancer.
Carboplatin Associated with Better Outcomes than Docetaxel in Advanced BRCA1/2-mutation Breast Cancer
Carboplatin is associated with better outcomes than docetaxel in individuals with BRCA1/2 mutation-harboring breast cancer.
Nab-Paclitaxel Yields Better pCR Rates than Paclitaxel in Neoadjuvant Taxane/Anthracycline Therapy
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel or nP) for breast cancer associated with improved pathologic complete response.
Adding Pictilisib to Anastrozole Might Better Control ER+, HER2-Negative Luminal B Tumor Proliferation
Adding the PI3K inhibitor pictilisib (GDC-0941) to anastrozole (ANA) improves antiproliferative response in breast cancer.
Tumor-Infiltrating Lymphocytes Implicate Pathway Activation in Immune Evasion
Increased post-neoadjuvant chemotherapy tumor-infiltrating lymphocytes associated with increased survival in triple-negative breast cancer (TNBC).
Molecular Subtyping Bests Standard in Predicting Breast Cancer Outcomes
Molecular tumor subtyping offers more accurate prediction of long-term breast cancer outcomes.
Neoadjuvant Veliparib Plus Carboplatin Holds Promise for TNBC
Adaptive randomization study finds neoadjuvant veliparib plus carboplatin may improve pCR in TNBC.
Switching Chemo Regimen After Cycle 1 Not Beneficial in Metastatic Breast Cancer
Patients with metastatic breast cancer did not benefit from switching to a second-line chemotherapy regimen after one cycle of first-line therapy.
Ramucirumab Does Not Improve Survival in Advanced Breast Cancer
Adding ramucirumab to docetaxel does not improve survival among patients with HER2-negative, advanced breast cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...